Transaction details
Vernon Rogers, who serves as Executive Vice President of Sales & Marketing at Aehr Test Systems (NASDAQ:AEHR), executed a sale of 5,000 shares of the company’s common stock on April 16, 2026. The shares sold at $86.88 apiece, generating gross proceeds of $434,400. The disposition was formally reported in a Form 4 filing submitted to the Securities and Exchange Commission.
Post-sale holdings
Following the transaction, Rogers is recorded as directly owning 161,633 shares of Aehr Test Systems. That total includes shares that remain subject to unvested restricted stock units, according to the filing.
Company developments and orders
Separately, Aehr Test Systems disclosed a record production order valued at $41 million from a hyperscale customer for package-level burn-in of custom AI processor ASICs. The order, described as the largest in the company’s history, will include Sonoma high-power package-level test and burn-in systems. Deliveries are scheduled to begin in fiscal 2027.
Financial results and backlog
For Q3 2026, Aehr Test Systems reported mixed results. The company posted earnings per share of -$0.05, which was better than consensus estimates of -$0.07. Revenue for the quarter was $10.3 million, below the $10.8 million that had been expected. Despite that revenue shortfall, quarterly bookings were substantial at $37.2 million, supporting an effective backlog that now exceeds $50 million.
Analyst reactions and market signals
Analysts have adjusted their targets in response to the company’s bookings momentum. Freedom Broker raised its price target to $61 and kept a Hold rating, while Lake Street increased its target to $56 and maintained a Buy rating, both citing the strength in bookings. Separately, InvestingPro analysis flagged the stock as appearing overvalued at current levels and noted that the relative strength index suggests the shares are in overbought territory.
Context and takeaways
The insider sale, the record-size hyperscale production order, solid quarterly bookings and the resulting backlog together paint a picture of strong demand metrics for Aehr Test Systems. At the same time, the company’s most recent quarter combined an earnings beat with a revenue miss, and market indicators cited by InvestingPro suggest valuation caution. The Form 4 disclosure documents the executive transaction, while analyst target revisions reflect differing views on near-term outlook and valuation.